serine has been researched along with mangiferin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, S; Brojen Singh, RK; Lebeche, D; Mangangcha, IR | 1 |
| Athipornchai, A; Chitnumsub, P; Leartsakulpanich, U; Maenpuen, S; Mee-Udorn, P; Phiwkaow, K; Pimviriyakul, P; Pinthong, C; Rungrotmongkol, T; Tinikul, R; Watchasit, S | 1 |
2 other study(ies) available for serine and mangiferin
| Article | Year |
|---|---|
Xanthone glucoside 2-β-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one binds to the ATP-binding pocket of glycogen synthase kinase 3β and inhibits its activity: implications in prostate cancer and associated cardiovascular disease risk.
Topics: Androgen Antagonists; Androgens; Cardiovascular Diseases; Glucosides; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Molecular Docking Simulation; Phosphates; Prostatic Neoplasms; Protein Isoforms; Serine; Xanthones | 2022 |
Mangiferin is a new potential antimalarial and anticancer drug for targeting serine hydroxymethyltransferase.
Topics: Antimalarials; Antineoplastic Agents; Folic Acid Antagonists; Glycine Hydroxymethyltransferase; Humans; Molecular Docking Simulation; Serine; Xanthones | 2023 |